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92121, USA.The TOE1 gene was discovered as a target of the Egr1 transcription factor that participates in cell
growth regulation through the upregulation of p21 and a cell cycle delay at the G2/M phase. We
report here that TOE1 is able to bind to the p53 tumor suppressor protein, speciﬁcally interacting
with the C terminal tetramerization domain of p53. We have further characterized this interaction
through determination of binding kinetics using nanoporous optical interferometry and demon-
strated that this interaction is capable of enhancing the transcriptional activity of p53-dependent
gene targets. These results suggest a mechanistic role for TOE1 as a co-regulator of p53.
Structured summary:
MINT-7144895: P53 (uniprotkb:P04637) physically interacts (MI:0914) with TOE1 (uniprotkb:Q96GM8)
by pull down (MI:0096)
MINT-7144912: TOE1 (uniprotkb:Q96GM8) binds (MI:0407) to P53 (uniprotkb:P04637) by biophysical
(MI:0013)
MINT-7144884: P53 (uniprotkb:P04637) physically interacts (MI:0914) with TOE1 (uniprotkb:Q96GM8)
by anti bait coimmunoprecipitation (MI:0006)
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
In our ongoing efforts to identify target genes for the Egr1 tran-
scription factor that may participate in its tumor suppressor func-
tion, we applied an approach based upon the cloning of in vivo
binding sites for DNA-binding proteins by chromatin immunopre-
cipitation. We have adapted this method to a PCR based protocol
allowing the cloning of cDNAs from a library and previously cloned
a gene we have named TOE1 for Target of Egr1 [1]. Sequence
homology analysis of the TOE1 gene revealed a unique nucleotide
and amino acid structure with the gene mapping to human chro-
mosome 1 within a region encompassing 1p34.1-3. Interestingly,
deletions in this same region are frequently associated with vari-
ous tumor genotypes with 1p deletion providing an accurate prog-
nostic indicator of therapeutic efﬁcacy [2]. The TOE1 gene lies
within a small region of the chromosome that has been shown to
harbor one or more potential tumor suppressor genes [3–5]. It re-
mains to be determined whether TOE1 displays regulated expres-
sion between normal versus tumor cells. Its localization to thechemical Societies. Published by E
Belle).
ive, Suite 120, San Diego, CAnucleus was, however, predicted based upon a stretch of basic ami-
no acid residues located toward the C terminus of the protein. We
have conﬁrmed that these residues are important for the nuclear
targeting of TOE1 since deletion of this region resulted in the cyto-
plasmic localization of TOE1. Although the precise biological func-
tion of TOE1 has not been determined, a deadenylating enzymatic
activity has recently been attributed to TOE1 [6].
We have shown that expression of TOE1 is associated with an
accumulation of cells in the G2/M cell cycle phase, as well as in-
creased expression of the cyclin dependent kinase inhibitor p21
[1]. The TOE1-mediated inhibition of cellular growth is consistent
with the effects of Egr1 expression [7], as well as with our previous
ﬁndings for Egr1 insofar as we observed a non-G1 cell cycle accu-
mulation of cells as well as increased p21 expression [8]. By this
criterion, TOE1 appears to act as an important mediator of the
growth effects of Egr1. Since it is well established that induction
of p21 expression is frequently associated with activation of p53,
and since p53 has been reported as a target gene for Egr1 [9], we
sought to determine whether the effects of TOE1 involved p53.
Our earlier studies showed that TOE1 expression did not result in
any apparent increase in the overall synthesis of p53, nor any
increase in the phosphorylation of p53 on serine 15, a common
indicator of its activation [1]. Since both p53 and TOE1 occupy a
similar cellular distribution within the nucleus and nucleolus, welsevier B.V. All rights reserved.
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fect p21 gene expression and impact cellular growth. In this study,
we present our data identifying an interaction between TOE1 and
p53 and describe the effect of this interaction on p21 activation.2. Materials and methods
2.1. Cell lines and culture conditions
293 and HeLa cells were cultured in DMEM medium containing
10% (v/v) fetal calf serum and supplemented with 2 mM L-gluta-
mine and grown in a humidiﬁed atmosphere of 5% CO2. For trans-
fection, cells were seeded the previous day and then transfected
with the appropriate plasmids using Lipofectamine 2000 (Invitro-
gen, Carlsbad, CA), according to the manufacturers instructions.
2.2. Co-immunoprecipitation
For co-immunoprecipitation assays, 293 cells were transfected
with the indicated plasmids. Cells were collected and washed with
cold PBS and then lysed in ice cold lysis buffer (50 mM HEPES, pH
7.6/250 mM NaCl/1 mM EDTA/1% (v/v) NP40). Lysates were soni-
cated for 2 s to break open nuclei, and incubated on ice for
15 min. Cell lysates were clariﬁed by centrifugation at 16 000g
for 10 min at 4 C and pre-cleared with protein A sepharose beads
for 1 h at 4 C with rotation. For immunoprecipitation, 1 lg of rab-
bit anti-p53 antibody (Santa Cruz Biotechnologies, Santa Cruz, CA),
was added and incubated overnight at 4 C with rotation. The next
day protein A sepharose beads were added and incubation contin-
ued for an additional 1 h. The beads were then washed four times
with lysis buffer, and suspended in SDS sample loading buffer.
Western blotting was then performed using a mouse anti-TOE1
monoclonal antibody (Abnova, Taipei, Taiwan).
2.3. GST pulldown assay
Bacterial expression constructs expressing full length, wild type
p53 or fragments consisting of amino acids 1–160, 160–320, 320–
393 as GST fusion proteins were kindly provided by Dr. James
Borowiec (NYU). Fusion proteins were expressed in bacteria fol-
lowing IPTG induction and puriﬁed using glutathione sepharose
beads. Quantitation of captured fusion protein was performed by
elution of an aliquot of the beads with reduced glutathione,
followed by protein concentration determination by the Bradford
assay. The purity of the recombinant proteins was assessed by
SDS–PAGE. About 293 cells were transfected with an expression
plasmid containing the cDNA for TOE1. Twenty-four hours after
transfection, the cells were lysed in the same buffer described for
co-immunoprecipitation. Cell lysates were mixed with beads con-
taining an equimolar concentration of each afﬁnity puriﬁed GST fu-
sion protein and mixed overnight at 4 C. The next day the beads
were washed four times with lysis buffer and suspended in SDS
sample buffer, and Western blotting was performed using a rabbit
afﬁnity puriﬁed anti-TOE1 antibody.
2.4. Nanoporous optical interferometry
For label free protein/protein interaction detection and kinetic
constant measurement, the SKi Pro (Silicon Kinetics, San Diego),
instrument was used with a ﬂow cell conﬁguration equipped with
an autosampler for sample delivery. SKi Pro uses derivatized nano-
porous silicon chips to allow crosslinking with biomolecules and
when incorporates a self-referenced channel when used in the ﬂow
cell conﬁguration to permit background, non-speciﬁc binding sub-
traction. Nanoporous carboxy chips were activated using sulfo-NHS/EDAC chemistry in a buffer consisting of 0.1 M MES pH 6,
0.15 M NaCl following the manufacturers guidelines (see www.sil-
iconkinetics.com). The chips were subsequently immobilized with
recombinant TOE1 expressed as a GST fusion protein at a concen-
tration of 5 lM in 20 mM sodium acetate, pH 4.5 and then blocked
with 1 M ethanolamine, pH 8.0. The indicated puriﬁed, recombi-
nant protein was provided for the binding reaction in phosphate
buffered saline, pH 7.2, and the optical interference pattern was re-
corded as a change in optical path difference in units of nm. For ki-
netic constant calculation, the analysis software package included
with the SKi Pro system was used.
2.5. Chromatin Immunoprecipitation
HeLa cells were cultured in a 10 cm plate as described above
and ﬁxed by adding to the culture medium 1/10 volume of a solu-
tion containing 11% HCHO, 50 mM Tris pH 8, 100 mM NaCl, 1 mM
EDTA for 20 min at room temperature with gentle agitation. Cells
were lysed in RIPA buffer modiﬁed to reach a ﬁnal concentration
of 0.5 M NaCl, and 1% SDS and supplemented with Complete prote-
ase inhibitors (Roche, Laval, Quebec). The lysate was sonicated for
5 cycles of 2000 at 10% power. Lysates were cleared by centrifuga-
tion for 100 at 16 000g and the supernatant was diluted with RIPA
minus SDS to obtain a ﬁnal concentration of 0.1% SDS. The samples
were incubated with 30 ll of protein A sepharose beads for 1 h at
4 C for preclearing. 10 ll of afﬁnity puriﬁed polyclonal anti-TOE1
antibody or pre-immune serum were added to the cleared super-
natant that were incubated o/n at 4 C. The day after 30 ll of pro-
tein A sepharose beads for were added for an additional 1 h at 4 C.
The beads were then washed four times with RIPA buffer, followed
by two washes in LiCl buffer (10 mM Tris pH 8, 0.25 M LiCl, 0.5%
NP40, 0.5% deoxycholate, 1 mM EDTA), and two washes in TE.
The crosslinking was reversed by incubation at 68 C o/n. DNA
was recovered by phenol/chloroform extraction followed by EtOH
precipitation in the presence of 20 lg of glycogen (Roche). After
precipitation the DNA was dissolved in H2O and 1/50 of the immu-
noprecipitate or 200 ng of input chromatin were subjected to PCR
with the following primers: GAGGGACTGGGGGAGGAGG
GAAG and CGGCAGCTGCTCACACCTCAGC for the p21 promoter,
and TGGTGTTGCAAGCAGGATCCAA and TCGGCTGGAGTTGCA-
GATGGA for the TLR2 promoter for 30 cycles.
2.6. Luciferase reporter assay
Freshly thawed HeLa cells were seeded in 24 well culture plates
and transfected in triplicate with 100 ng of reporter vector plasmid
together with 150 ng of each of the indicated expression vector as
described above. Twenty-four hours later, the cells were lysed in
100 mM KPO4, pH 7.8/0.2% (v/v) Triton X-100/1 mM DTT, and the
luciferase activity was measured using a EG&G Berthold Microplate
luminometer.3. Results
To test the hypothesis that TOE1 may form a complex with p53
through protein/protein interactions, our ﬁrst experiments were to
perform a co-immunoprecipitation assay from cells transfected
with TOE1 in the presence or absence of transfected, wild type
p53. For these experiments we have chosen 293 cells for their ease
of transfection. While these cells have been transformed with Ade-
novirus 5 DNA, we overexpressed wild type p53 by transfection to
detect protein/protein interaction. As shown in Fig. 1, we were able
detect an interaction between p53 and TOE1 by co-immunoprecip-
itation. These results suggest that p53 and TOE1 are capable of
interacting. To test whether the protein/protein interaction
Fig. 1. Co-immunoprecipitation of TOE1 with p53. About 293 cells were transfected
with empty vector (pcDNA3), or vectors expressing p53 alone or together with
FLAG-tagged TOE1. Following transfection cells were incubated for 24 h at 37 C.
Cell lysates were immunoprecipitated with rabbit anti-p53 antibodies, and Western
blots probed for either p53 or FLAG-TOE1 using mouse antibodies.
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immunoprecipitation experiment using a mutant version of TOE1
that does not enter the nucleus. We observed no interaction be-
tween p53 and the non-nuclear mutant of TOE1 (data not shown).
p53 is known to interact with a large number of protein part-
ners and has been shown to bind non-speciﬁcally to many more
[10]. To test the speciﬁcity of interaction between TOE1 and p53
we performed in vitro GST pulldown assays using puriﬁed recom-
binant proteins. TOE1 was expressed as a full length GST fusionFig. 2. GST pulldown of TOE1 with the C terminal domain of p53. (A) Schematic diagram
amino acids indicated. Not drawn to scale. (B) SDS–PAGE of the expressed and puriﬁed GS
at the left. (C) Western blot detection of TOE1 following GST pulldown assay. The indica
TOE1 detected using afﬁnity puriﬁed rabbit anti-TOE1 antibodies.protein while GST-p53 fusion proteins were expressed as either
full length or as truncated proteins. The GST-p53 fusion constructs
used, representing the N terminal activation, central DNA-binding
and C terminal tetramerization domains and as shown in Fig. 2A.
Fig. 2B shows a Coomassie blue stained gel of the recombinant
puriﬁed proteins used for the pulldown experiments. To detect a
potential interaction between TOE1 and p53, equimolar amounts
of each GST-p53 construct, captured on glutathione beads, were
mixed with TOE1 to allow binding to occur. Following washes,
the beads were eluted with SDS sample buffer and analysed by
SDS–PAGE and Western blotting using TOE1 anti-serum. The re-
sults of the pulldown experiments are shown in Fig. 2C and show
that puriﬁed, recombinant TOE1 was capable of interacting with
both full length p53 as well as displaying a strong interaction with
the C terminal tetramerization domain of p53. The small amount of
interaction seen with the N terminal portion of p53 we consider to
be non-speciﬁc as the same signal can be seen using the control
GST protein alone. These results conﬁrm that TOE1 can interact
with p53 and furthermore support that this interaction occurs
via the C terminal tetramerization domain in p53.
In order to further characterize the interaction between TOE1
and p53 we determined the binding afﬁnity kinetic constants using
nanoporous optical interferometry [11]. This technology uses
nanoporous silicon chips derivatized with carboxylated polyethyl-
ene glycol to permit protein immobilization via amine coupling
using NHS/EDAC ester crosslinking. Once the nanoporous silicon
chip has been immobilized with receptor protein a target protein
is provided to the chip using microﬂuidics. Upon binding, the opti-
cal interference pattern is measured and recorded as a sensorgram
allowing the quantitation of binding kinetic constants. Using the
SKi Pro bisensor interaction instrument we were able to detect
an interaction between immobilized TOE1 with the C terminalof the p53 GST fusion proteins used in the pulldown assay with the corresponding
T fusion proteins used in the pulldown assays. Molecular weight markers are shown
ted GST fusion protein was incubated with 293 cell extracts expressing TOE1, and
Fig. 3. Nanoporous optical interferometry measurement of binding kinetics. (A)
Puriﬁed recombinant TOE1 was immobilized to a carboxy chip at a concentration of
5 lM. Following chip blocking, the chip was provided with target protein in the
ﬂow cell at a concentration of 2000 nM in PBS binding buffer. (B) TOE1 immobilized
to a carboxy chip was provided with the C terminal GST-p53 domain at
concentrations varying from 400 to 1000 nM in PBS binding buffer.
Table 1
Table of kinetic binding constants. Table shows calculated kinetic binding constants
for the interaction between immobilized TOE1 and GST-p53 representing residues
320–393.
Interaction ka (M1 s1) kd (s1) Kd (M)
TOE1 + p53 C terminus 1.27  103 1.7  104 7.2  108
Fig. 4. Binding and activation of p53-responsive promoter by p53 and TOE1. (A) ChIP
negative control (TLR2) from chromatin immunoprecipitated with anti TOE1 antibody. (B
p21 or PTEN promoter together with the indicated expression vectors. Control samples w
cells were collected and assayed for luciferase activity by luminometry. Results are prese
error bars.
2168 S. Sperandio et al. / FEBS Letters 583 (2009) 2165–2170domain, but not with the N terminal or central DNA-binding do-
main of p53 (Fig. 3A). Further, we did not observe any interaction
with the GST moiety alone. To determine the afﬁnity between
TOE1 and the p53 C terminal domain, we again used SKi Pro nano-
porous optical interferometry. As previously, TOE1 was immobi-
lized to the nanoporous silicon chip and the C terminal domain
of p53 was provided at varying concentrations. Fig. 3B shows the
sensorgrams of the binding reactions. Following data collection,
the kinetic parameters and afﬁnity constants were calculated using
the SKi Pro kinetic analysis package and results for the kinetic con-
stants are presented in Table 1.
Using a variety of methodologies, the combined experiments
described above provide consistent evidence that TOE1 is capable
of speciﬁc interaction with the C terminal tetramerization
domain of p53. In addition, we have shown previously that
expression of TOE1 increases p21 levels [1]. Since p53 is a known
transactivator of p21, we sought to determine whether the inter-
action between TOE1 and p53 could be detected in vivo on the
p21 promoter.
As shown in Fig. 4A, anti-TOE1, but not pre-immune, immuno-
precipitates contained sequences corresponding to the p21 pro-
moter. As a negative control, primers for the TLR2 promoter
showed no ampliﬁcation from the same immunoprecipitates.
These results indicate that TOE1 can be found in vivo in a complex
containing the p21 promoter.of TOE1 bound to p21 promoter. PCR ampliﬁcation of the p21 promoter but not a
and C) HeLa cells were transfected with a luciferase reporter vector containing the
ere transfected with empty expression vector. Twenty-four hours after transfection,
nted as the average of tripicate samples with the standard deviations indicated with
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tional consequences to the biological function of p53, we examined
the transcriptional activation of two eukaryotic promoters known
to be induced by p53, in the presence or absence of TOE1. We chose
to look at the effects on the PTEN promoter since it is known to be
p53 and Egr1 activated and is a recognized tumor suppressor gene
[12,13]. Additionally, we examined the transcriptional effects on
the p21 promoter because of its known targeting by p53 as well
as the documented upregulation of p21 following TOE1 expression
[1,14,15]. As shown in Fig. 4B and C, while both reporter genes
were activated by p53 as expected [12], TOE1 alone had no or a
marginal effect on reporter gene activation. However when both
proteins were co-expressed we observed a TOE1 dependent
enhancement of p53 transactivation. This suggested that the
interaction between TOE1 and p53 may have functional
signiﬁcance with respect to augmenting the transactivation poten-
tial of p53.
4. Discussion
It has been well established that the Egr1 and p53 growth inhib-
itory effects display considerable overlap [8,16,17]. Both proteins
are capable of producing growth inhibition, likely through activa-
tion of key common target genes exempliﬁed by p21 and PTEN.
Establishing the key biological activities of TOE1 will allow us to
proceed to address our hypothesis that Egr1 and p53 mediated
growth inhibition may include the activity of TOE1. It is estimated
that p53 mutations occur in roughly 50% of human cancers [18],
and the identiﬁcation of a modulator of p53 function would be a
signiﬁcant advance in understanding both the regulation of p53
activity as well as possibly contributing to furthering the under-
standing of tumor biology.
In our studies we have demonstrated that TOE1 makes physical
contact with p53 using multiple independent methods.
Additionally, we have characterized the kinetic association con-
stants between these two proteins using nanoporous optical inter-
ferometry. Our afﬁnity constant determinations suggest that TOE1
binding to p53 demonstrates a high afﬁnity binding capability with
a Kd of 72 nM. This afﬁnity is within the same range as the previ-
ously published afﬁnity constant between p53 and Bcl2 [19]. Our
results indicate that the binding surface for TOE1 lies within the
C terminal portion of p53 responsible for protein tetramerization.
It is possible that TOE1 may exert its effects on p53 by stabilizing
the active tetrameric form of the protein, to promote DNA-binding.Fig. 5. Model for TOE1 as a co-activator of gene expression leading to growth
suppression. Proposed model for the cooperation between Egr1 and p53 in
activating target genes leading to growth/cell cycle arrest. Egr1 and p53 both
activate PTEN, TGFb1and p21 genes. TOE1 is shown as an Egr1 target gene that
binds to and augments the activity of p53. In this way, Egr1 enhances the
cooperative effect with p53 by inducing its activator.Other possibilities include, but are not limited to, facilitating
other protein/protein interactions, altering p53 degradation, affect-
ing nuclear export and inﬂuencing p53 post-translational
modiﬁcation.
Since there are a large number of p53 binding partners, the
identiﬁcation of an additional p53 binding protein requires a
demonstration that the interaction serves a biologically signiﬁ-
cant role. We show here that the binding of TOE1 to p53 en-
hances the transactivation function of p53 on two independent
p53 responsive promoters; p21 and PTEN. In addition, we show
proof of an in vivo association of TOE1 with the p21 promoter,
likely through the interaction with p53. Thus, we propose that
the effects of TOE1 on growth inhibition might function through
a signal-directed interaction with p53 resulting in a change in
the activity of p53. A model for this hypothesis is shown in
Fig. 5. We propose that the overlapping effects demonstrated be-
tween Egr1 and p53 may be mediated by TOE1. In this model,
activation of Egr1 leads to increased expression of TOE1, which
subsequently binds to p53. This interaction promotes the p53-
dependent activation of its target genes including p21 and PTEN
to favor cell cycle arrest and growth inhibition. In this manner,
we propose that TOE1 is capable of integrating the effects of
Egr1 and p53 and thereby serves as a biologically important tar-
get of Egr1 with respect to its tumor suppressor activity as well
as a co-regulator of the p53 tumor suppressor function. We are
initiating genetic knock out studies to allow us to address these
and other aspects of TOE1 function in greater detail.
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